Loss of Muscle Mass Is a Novel Predictor of Postoperative Early Recurrence in N2-Positive Non-Small-Cell Lung Cancer

Takuma Tsukioka, MD, PhD, Nobuhiro Izumi, MD, PhD, Chung Kyukwang, MD, PhD, Hiroaki Komatsu, MD, PhD, Michihito Toda, MD, PhD, Kantaro Hara, MD, and Noritoshi Nishiyama, MD, PhD

Background: We often experienced early recurrence in patients with completely resected N2-positive non-small-cell lung cancer (NSCLC). Loss of muscle mass is a poor prognostic factor in patients with several stages of NSCLC. This study aimed to investigate the relationship between preoperative loss of muscle mass and postoperative early recurrence in patients with N2-positive NSCLC.

Methods: We retrospectively analyzed 47 male patients with completely resected pathological N2-positive NSCLC. Early recurrence was defined as that diagnosed within 1 year after the operation. We used the L3 muscle index (cross-sectional area of muscle at the L3 level, normalized for height) as a clinical measurement of loss of muscle mass (cutoff value, 52.4 cm²/m²).

Results: In all, 18 patients with early recurrence had significantly poorer outcomes compared with those without (P < 0.01). In univariate analysis, loss of muscle mass (P = 0.023), carcinoembryonic antigen (CEA) level > 5.0 ng/mL (P = 0.002), and absence of postoperative chemotherapy (P = 0.042) were predictors of postoperative early recurrence. In multivariate analysis, loss of muscle mass (P = 0.004) and CEA level > 5.0 ng/mL (P = 0.001) were independent predictors.

Conclusions: Loss of muscle mass is an independent predictor of postoperative early recurrence in pathological N2-positive NSCLC patients.

Keywords: non-small-cell lung cancer, early recurrence, loss of muscle mass, mediastinal lymph node metastasis

Introduction

Survival after surgery of non-small-cell lung cancer (NSCLC) with mediastinal lymph node (N2) metastasis remains poor. We often experienced postoperative early recurrence in patients with completely resected N2-positive NSCLC. Prediction of early recurrence may contribute to select a good prognostic group in these patients. Thus, we consider prediction of early recurrence as a significantly meaningful action in patients with N2-positive NSCLC.

Loss of muscle mass is a poor prognostic factor in patients with clinical stage III to IV NSCLC or small-cell lung cancer who are treated with chemotherapy.\(^1\),\(^2\) We previously reported that loss of muscle mass was a significant postoperative poor prognostic factor in patients with stage I NSCLC.\(^3\) There is no report investigating the correlation between loss of muscle mass and postoperative early recurrence.
In the present study, we analyzed the relationship between preoperative loss of muscle mass and postoperative early recurrence in patients with completely resected N2-positive NSCLC.

Materials and Methods

Of 725 patients who underwent definitive pulmonary resection with mediastinal lymph node dissection for primary lung cancer at our hospital from January 2003 to December 2012, we retrospectively analyzed 47 male patients with pathological N2-positive NSCLC. Patients who had preoperative treatments or whose tumors were not completely removed were excluded. Patients who underwent pneumonectomy, pulmonary segmentectomy, or partial resection were also excluded. Informed consent for application of the patients’ examination outcomes and data of clinical courses was obtained before surgery in all of the patients. This study was approved by the local institutional ethical committee.

The mediastinal lymph nodes were clinically diagnosed as positive for metastasis when more than 10 mm in short axis was calculated using enhanced computed tomography (CT). Patients with distant metastasis, mediastinal lymph node metastasis at more than two stations, bulky mediastinal lymph node metastasis and contralateral mediastinal lymph node metastasis were not candidates for surgery. Patients with a predicted postoperative forced expiratory volume in 1 second of less than 40% were also ineligible for surgery. We used the 7th edition of the tumor node metastasis (TNM) Classification of Malignant Tumors to determine the pathological stage.

After discharge, all of the patients got follow-up examination every 2 to 4 months by chest X-ray and for tumor markers, and every 6 months by CT. Recurrence diseases were commonly detected by imaging methods. Early recurrence diseases were defined as those detected within 1 year after operation. The last follow-up review was conducted on August 31, 2017.

We used the cross-sectional area (cm²) of skeletal muscle at the third lumbar vertebral (L3) level on CT as a barometer of systemic muscle mass. The L3 muscle index (L3MI) is a clinical indicator of loss of muscle mass, and calculated by the cross-sectional area of muscle at the L3 level with normalized for height (cm²/m²; as with body mass index). Yoshizumi et al. reported that the measured skeletal muscle area at L3 was correlated with body surface area (BSA) significantly. They created a formula to calculate skeletal muscle area at L3 using BSA as follows: BSA (m²) = 71.84 × height⁰.⁷₂₅ × body-weight⁰.⁴₂⁵ × 10⁻⁴. Skeletal muscle area at L3 (cm²) for males = 126.9 × BSA – 66.2. We used this formula to calculate the L3MI. The cutoff value for the L3MI was 52.4 cm²/m² for males according to a previous report, and patients with an L3MI <52.4 cm²/m² were defined as those with loss of muscle mass.

The prognostic nutritional index (PNI) is a clinical indicator of nutritional status, and calculated by the serum albumin level and the total peripheral blood lymphocyte count as follows: PNI = 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/uL).

Platinum-doublet chemotherapy was performed as postoperative adjuvant therapy. However, because an indication for adjuvant chemotherapy was not established, the decision was depended on each physician’s empirical concept.

We collected blood samples within 1 month before surgery, and measured body height and weight on admission. Median age in this study population (68 years) was used as a cutoff value for age. We used 18.5 kg/m² as a cutoff value for body mass index according to the guidelines of the World Health Organization. We defined cutoff values for tumor markers according to previous reports.

We used χ² test and Mann–Whitney U-test to compare the clinicopathologic factors of patients with and without early recurrence. The Kaplan–Meier method was used to investigate overall survival and the log-rank test was used to assess differences. Logistic regression analysis was used for univariate analysis and multiple logistic regression was used for multivariate analysis. Odds ratios were used to estimate the relative risk for early recurrence. P < 0.05 was considered significant. Statistical analyses were performed using JMP 10 software (SAS Institute, Cary, NC, USA).
Results

The median follow-up period was 37 months, during which 37 patients had recurrent disease and 18 had early recurrence. The first recurrent sites were the lungs in 10, bone in 9, lymph nodes in 9, liver in 3, brain in 3, adrenal gland in 2, and kidney and carcinomatous pleuritis in one patient each. The first recurrent sites in early recurrence cases were bone in seven, lymph nodes, lung, and liver in three each, and the adrenal gland, brain, and carcinomatous pleuritis in one patient each. The patients with early recurrence had a significantly poorer prognosis compared with those without early recurrence, with 5-year survival rates of 6% and 64%, respectively ($P < 0.01$; Fig. 1). Characteristics of patients according to the presence of early recurrence are shown in Table 1. Early recurrence was significantly associated with L3MI values, tumor size, and the status of postoperative chemotherapy. Postoperative complications were observed in 15 patients, including prolonged air leakage in eight, arrhythmia in three, and pneumonia and chylothorax in two patients each. There was no significant difference in the presence of complications according to the presence of early recurrence ($P = 0.968$).

In univariate analysis, an L3MI $<52.4\, \text{cm}^2/\text{m}^2$, carcinoembryonic antigen (CEA) levels $>5.0\, \text{ng/mL}$, and absence of postoperative chemotherapy were significant predictors of postoperative early recurrence. When these factors and tumor size $>37\, \text{mm}$ were subjected to multivariate analysis, an L3MI $<52.4\, \text{cm}^2/\text{m}^2$ and CEA levels $>5.0\, \text{ng/mL}$ were independent predictors (Table 2).

Table 1 Characteristics of patients according to the presence of early recurrence

| Characteristics                        | Early recurrence | All (n = 47) | Yes (n = 18) | No (n = 29) | $P$ value |
|----------------------------------------|------------------|-------------|-------------|-------------|----------|
| Age (years)                            |                  | 68 (35, 84) | 73 (35, 80) | 63 (47, 84) | 0.463    |
| Performance status                     |                  |             |             |             |          |
| 0                                      |                  | 38          | 14          | 24          | 0.376    |
| 1                                      |                  | 8           | 3           | 5           |          |
| 2                                      |                  | 1           | 1           | 0           |          |
| Smoking index                          |                  | 890 (0, 2580)| 810 (0, 2800) | 0.983      |
| BMI (Kg/m$^2$)                         |                  | 20.9 (16.7, 29.8) | 22.6 (15.9, 30.9) | 0.108      |
| L3MI (m$^2$/cm$^2$)                    |                  | 51.2 (44.7, 62.4) | 53.9 (45.6, 64.5) | 0.043      |
| PNI                                    |                  | 53.2 (44.5, 65.5) | 54.9 (40.0, 63.9) | 0.441      |
| Respiratory function                   |                  |             |             |             |          |
| %VC (%)                                |                  | 106 (81, 127) | 104 (70, 142) | 0.717      |
| %FVC (%)                               |                  | 106 (71, 127) | 104 (67, 142) | 0.824      |
| FEV1.0% (%)                            |                  | 76 (56, 93)   | 75 (55, 96)   | 0.851      |
| Clinical stage                          |                  |             |             |             |          |
| I                                      |                  | 31          | 11          | 20          | 0.266    |
| II                                     |                  | 8           | 5           | 3           |          |
| III                                    |                  | 8           | 2           | 6           |          |
| CEA (ng/mL)                            |                  | 10.9 (2.8, 131) | 4.6 (1.2, 1194) | 0.072      |
| CYFRA (ng/mL)                          |                  | 2.2 (0.7, 13.7) | 1.9 (0.5, 31.4) | 0.718      |
| Tumor size (mm)                        |                  | 37 (15, 83)  | 43 (24, 83)  | 32 (15, 70) | 0.035    |
| Histological subtypes                  |                  |             |             |             |          |
| Adenocarcinoma                         |                  | 37          | 14          | 23          | 0.901    |
| Non-adenocarcinoma                     |                  | 10          | 4           | 6           |          |
| Pathological stage                     |                  |             |             |             |          |
| IIA                                    |                  | 37          | 13          | 24          | 0.400    |
| IIIB                                   |                  | 10          | 5           | 5           |          |
| Status of N2 nodal extension           |                  |             |             |             |          |
| Skip/sequential                       |                  | 5/13        | 20/9        | 0.812      |
| Single/multiple                       |                  | 12/6        | 18/11       | 0.749      |
| Postoperative chemotherapy             |                  |             |             |             |          |
| Yes / No                               |                  | 7/11        | 20/9        | 0.042      |

Values are median (range). BMI: body mass index; L3MI: L3 muscle index; PNI: prognostic nutritional index; %VC: percent of vital capacity; %FVC: percent of forced vital capacity; FEV1.0%: percent of forced expiratory volume in 1 second; CEA: carcinoembryonic antigen; CYFRA: cytokeratin 19 fragment.
There were no significant differences in blood leucocyte count and C-reactive protein levels (Fig. 2). The neutrophil/lymphocyte ratio (NLR) was significantly higher in patients with loss of muscle mass than in those without ($P = 0.030$, Fig. 3).

**Discussion**

Several clinicopathological factors\(^{12}\) and proliferative molecular factors\(^{13,14}\) were reported as significant predictors of postoperative recurrence in N2-positive NSCLC. This is the first report to investigate the relationship between early recurrence and loss of muscle mass in patients with completely resected N2-positive NSCLC. We showed a poor prognostic effect of decreased muscle mass on cancer recurrence. In patients with muscle deficiency, operations should be selected after careful deliberation, and more frequent postoperative follow-up examinations may be required.

We showed that the NLR was significantly higher in patient with loss of muscle mass compared with those without. Elevation of the NLR indicates infiltration of

| Table 2 Univariate and multivariate analyses of risk factors for early recurrence |
|------------------|---------------|------------------|------------------|------------------|---------------|------------------|
|                  | Univariate analysis |               |                 |                | Multivariate analysis |               |                 |                |
|                  | n              | HR 95% CI     | P value         | HR 95% CI     | P value         |                   |                 |                |
| Age              |                |               |                 |                |                 |                   |                 |                |
| >68              | 23             | 2.23          | 0.68–7.69       | 0.187          |                 |                   |                 |                |
| ≤68              | 24             | 0.73          | 0.17–3.37       | 0.675          |                 |                   |                 |                |
| Performance status |                |               |                 |                |                 |                   |                 |                |
| 0, 1-2           | 38, 9         | 0.40          | 0.07–2.08       | 0.273          |                 |                   |                 |                |
| BMI (kg/m\(^2\)) |                |               |                 |                |                 |                   |                 |                |
| ≥18.5            | 40             | 0.24          | 0.07–0.82       | 0.023          | 0.10            | 0.01–0.50        | 0.004          |
| <18.5            | 7              | 0.59          | 0.12–2.88       | 0.506          |                 |                   |                 |                |
| L3MI (m\(^3\)/cm\(^2\)) |          |               |                 |                |                |                   |                 |                |
| ≥52.4            | 28             | 9.23          | 2.10–65.68      | 0.002          |                  |                   |                 |                |
| ≤52.4            | 18             | 1.25          | 0.34–4.50       | 0.733          |                 |                   |                 |                |
| PNI              |                |               |                 |                |                 |                   |                 |                |
| ≥50              | 39             | 0.28          | 0.08–0.96       | 0.042          | 0.57            | 0.12–2.74        | 0.477          |
| <50              | 8              | 0.40          | 0.17–1.52       | 0.559          |                 |                   |                 |                |
| CEA (ng/mL)      |                |               |                 |                |                 |                   |                 |                |
| >5.0             | 29             | 19.3          | 2.95–236.54     | 0.001          |                 |                   |                 |                |
| ≤5.0             | 18             | 0.30          | 0.07–1.21       | 0.195          |                 |                   |                 |                |
| CYFRA (ng/mL)    |                |               |                 |                |                 |                   |                 |                |
| >3.5             | 32             | 3.09          | 0.69–16.84      | 0.143          |                 |                   |                 |                |
| ≤3.5             | 15             | 0.57          | 0.12–2.74       | 0.477          |                 |                   |                 |                |
| Tumor size (mm)  |                |               |                 |                |                 |                   |                 |                |
| >37              | 23             | 0.28          | 0.08–0.96       | 0.042          | 0.57            | 0.12–2.74        | 0.477          |
| ≤37              | 24             | 0.40          | 0.17–1.52       | 0.559          |                 |                   |                 |                |
| Postoperative chemotherapy | |               |                 |                |                 |                   |                 |                |
| Yes              | 27             | 2.23          | 0.68–7.69       | 0.187          |                 |                   |                 |                |
| No               | 20             | 0.73          | 0.17–3.37       | 0.675          |                 |                   |                 |                |

HR: hazard ratio; CI: confidence interval; BMI: body mass index; L3MI: L3 muscle index; PNI: prognostic nutritional index; CEA: carcinoembryonic antigen; CYFRA: cytokeratin 19 fragment
Loss of Muscle Mass Is a Predictor of Early Recurrence

Chemotherapy on postoperative early recurrence remains unclear in patients with muscle deficiency. A criterion of indication for adjuvant chemotherapy should be established and accumulation of patients' data is necessary. If tumor-associated inflammation is the cause of muscle deficiency and a poor prognosis, anti-inflammatory treatments should be introduced to improve the prognosis. IL-6 is an important pro-inflammatory cytokine, and plays a crucial role in cancer progression. An anti-IL-6 antibody has been reported to have beneficial effect on cancer treatments either as a single agent or in combination with other anticancer drugs.21)

This study has some limitations. First, this was a retrospective study that included only a small number of patients. Second, we used 52.4 cm²/m² as the cutoff value for L3MI because this value was widely used in several articles.5) However, Kimura et al.1) reported that the L3MI cutoff values in Japanese patients with inoperable stages III to IV NSCLC was 41.0 cm²/m² for males. It may be important to use appropriate cutoff values based on disease stage, cancer type, and ethnicity. Third, the formula which calculated skeletal muscle area using BSA was produced by physical findings in healthy adults. Because almost all patients in this study were categorized as PS 0 and 1, we used this formula. The measurement error of the L3MI could be reduced by use of this formula and an unnecessary CT at the lumbar vertebral level could be avoided. Forth, although we considered tumor-associated inflammation might be a crucial reason for the loss of muscle mass, other unrevealed reasons, such as tumor-unrelated inflammation, should be explored in further examinations.

In conclusion, loss of muscle mass is an independent predictor of early recurrence in patients with pathological N2-positive NSCLC. Tumor-related inflammation might be an important reason for muscle deficiency and poor prognosis. Loss of muscle mass may become a novel biomarker for determining the treatment strategy for patients with N2-positive NSCLC.

Disclosure Statement

The authors have no relevant financial or other potential conflicts of interest in this manuscript.

References

1) Kimura M, Naito T, Kenmotsu H, et al. Prognostic impact of cancer cachexia in patients with advanced
12) Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 146: 788-95.

13) Matsuwaki R, Ishii G, Zenke Y, et al. Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma. Cancer Sci 2014; 105: 905-11.

14) Chen G, Liu XY, Wang Z, et al. Vascular endothelial growth factor C: the predictor of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg 2010; 37: 546-51.

15) Nagaraj S, Schrum AG, Cho HI, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010; 184: 3106-16.

16) Wang J, Kalhor N, Hu J, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with poor survival in patients with stage I-III non-small cell lung cancer. PLoS ONE 2016; 11: e0163397.

17) Takahashi Y, Kawamura M, Hato T, et al. Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection. World J Surg 2016; 40: 365-72.

18) Tomita M, Shimizu T, Ayabe T, et al. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 2012; 32: 3535-8.

19) Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12: 249-56.

20) Fishman P, Bar-Yehuda S, Vagman L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res 1998; 58: 3181-7.

21) Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141: 125-39.